All Updates

All Updates

icon
Filter
Funding
Talus Bioscience raises USD 4.3 million in grant funding
AI Drug Discovery
Aug 18, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Aug 18, 2023

Talus Bioscience raises USD 4.3 million in grant funding

Funding

  • Seattle-based AI drug discovery startup Talus Biosciences has secured USD 2.3 million in non-dilutive grant funding from the Andy Hill Cancer Research Endowment (CARE) Fund and an additional USD 2 million small business innovation research (SBIR) grant from the National Institutes of Health, which brings a total fund of USD 4.3 million.

  • The funding will be used to speed up the development of novel transcription factor inhibitors for two pediatric cancers, rhabdomyosarcoma and neuroblastoma, and accelerate the development of transcription factor drugs.

  • Founded in 2020, Talus Biosciences develops novel therapeutics focusing on previously undruggable transcription factors—proteins that regulate all genes in a person's genetic material by attaching to DNA and activating or deactivating the switches that determine gene activity. The company leverages its proprietary drug discovery platform, Multiplexed Assays for Rational Modulation of Transcription Factors (MARMOT), which combines AI, synthetic chemistry, and proteomics to accelerate the discovery and development of novel drugs.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.